TSHA Earnings Prediction
The chart below shows how TSHA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TSHA sees a +6.64% change in stock price 10 days leading up to the earnings, and a +3.47% change 10 days following the report. On the earnings day itself, the stock moves by +19.37%. This data can give you a slight idea of what to expect for the next quarter's release.
TSHA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.79M
-62.33%
60.79%
Gross Margin
--
--
--
Operating Margin
-1177.85%
257.56%
-38.51%
Net Margin
-1427.52%
-42.14%
-24.15%
EPS
-0.10
-89.25%
11.11%
No Data Available
TSHA Earnings Analysis
Taysha Gene Therapies, Inc. Common Stock Corporation (TSHA.O) Earnings Conference Call
Positive
R&D Expense Increase: Research and development expenses were $14.9 million for the three-month ended September 30, 2024, compared to $11.8 million for the three-month ended September 30, 2023, reflecting a $3.1 million increase driven by a $0.8 million increase in GMP batch activity during the three-month ended September 30, 2024.
Net Loss Reduction: Net loss for the three-month ended September 30, 2024, was $25.5 million or $0.10 per share, compared to a net loss of $117.1 million or $0.93 per share for the three-month ended September 30, 2023, indicating a significant reduction in net loss.
Cash Reserves and Projections: As of September 30, 2024, Tayesha had $157.7 million in cash and cash equivalents, which is expected to support planned operating expenses and capital requirements into the fourth quarter of 2026.
TSH-A-102 Program Progress: The company continues to drive progress across its TSH-A-102 program and remains confident in the potential of TSH-A-102 to provide therapeutic benefit to adult, adolescent, and pediatric patients with Rett syndrome.
FDA Submission Confirmation: The FDA has confirmed that the existing non-clinical data package is adequate to support BLA submission, and the company is aligned on a meeting cadence with the FDA to expedite the development plan for TSH-A-102.
Negative
R&D Expense Increase: Research and development expenses were $14.9 million for the three-month ended September 30, 2024, compared to $11.8 million for the three-month ended September 30, 2023, indicating a $3.1 million increase driven by a $0.8 million increase in GMP batch activity.
Administrative Expense Reduction: General and administrative expenses were $7.9 million for the three-month ended September 30, 2024, compared to $8.6 million for the three-month ended September 30, 2023, reflecting a reduction of $0.7 million primarily due to the decrease in issuance costs allocated to liability-classified 2023 pre-funded warrants associated with the August 2023 financing.
Net Loss Reduction: Net loss for the three-month ended September 30, 2024, was $25.5 million or $0.10 per share, compared to a net loss of $117.1 million or $0.93 per share for the three-month ended September 30, 2023, indicating a significant reduction in net loss but still reflecting substantial ongoing losses.
Net Loss Reduction Factors: The reduction in net loss in 2024 was primarily due to an non-cash loss of $100.5 million reported in 2023 from a change in fair value of warrant liability from the 2023 pre-funded warrants associated with the August 2023 financing.
Liquidity Concerns Ahead: As of September 30, 2024, Tayasha had $157.7 million in cash and cash equivalents, which is expected to support planned operating expenses and capital requirements into the fourth quarter of 2026, indicating a potential liquidity concern as they approach the end of their cash runway.
TSHA FAQs
How does TSHA typically perform around its earnings report dates?
Is Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TSHA Earning Call Sentiment
Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TSHA.O
3.03%Positive
The earnings call summary shows mixed signals. The financial performance is slightly positive with reduced net loss and strong cash reserves, but the increased R&D expenses and lack of specific guidance on trial endpoints are concerns. The Q&A section highlights potential challenges in trial design and endpoint selection, which could cause uncertainty. While there is positive demand for trials, the refusal to provide updates on certain endpoints and unclear management responses may worry investors. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in either direction.
